XOMA Royalty (XOMA) Expected to Post Quarterly Earnings on Wednesday

XOMA Royalty (NASDAQ:XOMA) is expected to be posting its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect XOMA Royalty to post earnings of $0.18 per share and revenue of $13.91 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). The company had revenue of $12.32 million during the quarter, compared to analyst estimates of $13.91 million. XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. On average, analysts expect XOMA Royalty to post $1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

XOMA Royalty Price Performance

Shares of NASDAQ XOMA opened at $40.17 on Wednesday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 3.59 and a current ratio of 3.59. The firm has a fifty day moving average of $41.61 and a 200 day moving average of $35.30. The firm has a market cap of $503.77 million, a PE ratio of 25.59 and a beta of 0.86. XOMA Royalty has a one year low of $22.29 and a one year high of $45.22.

Institutional Trading of XOMA Royalty

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 543 shares during the period. Russell Investments Group Ltd. lifted its holdings in XOMA Royalty by 3,436.4% in the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares during the last quarter. Dimensional Fund Advisors LP grew its position in XOMA Royalty by 4.5% in the third quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock worth $1,124,000 after acquiring an additional 1,269 shares during the period. Tower Research Capital LLC TRC grew its position in XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares during the period. Finally, Barclays PLC increased its stake in XOMA Royalty by 12.1% during the fourth quarter. Barclays PLC now owns 14,822 shares of the biotechnology company’s stock worth $394,000 after acquiring an additional 1,598 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on XOMA. Weiss Ratings upgraded shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 29th. Zacks Research upgraded XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. HC Wainwright cut XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a report on Thursday, April 30th. Lucid Cap Mkts downgraded XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Benchmark lowered XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. One research analyst has rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, XOMA Royalty has a consensus rating of “Hold” and a consensus price target of $53.75.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.